Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma, Clear Cell × dostarlimab × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Osteosarcoma 2 Triple Negative Breast Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma 1 Rhabdomyosarcoma 1 Pathologic Complete Response 1 Ovarian Carcinosarcoma 1 Neuroblastoma 1 Neoplasm Metastasis 1 Melanoma 1 Hodgkin Disease 1 Hepatoblastoma 1 Hemangiosarcoma 1 Glioblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Ependymoma 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Neuroendocrine 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Adrenocortical Carcinoma 1

Interventions

Cyclophosphamide 4 Topotecan 3 Ifosfamide 3 Doxorubicin 3 seclidemstat 2 pazopanib 2 Biopsy 2 tebentafusp 1 selinexor 1 pembrolizumab 1 pegylated granulocyte colony-stimulating factor 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 devimistat 1 cobimetinib 1 atezolizumab 1 Zoledronic Acid 1 X-Rays 1 Vemurafenib 1 Sunitinib 1 Specimen Handling 1 Sirolimus 1 Simvastatin 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Radiation 1 Proton Therapy 1 Nivolumab 1 Methotrexate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04274023 2024-02-01

ACCeSs

Italian Sarcoma Group

Phase 2 Terminated

Sarcoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡